CLMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now: near-term technical momentum is weakening (MACD histogram negative and expanding) and the pattern-based forecast points to further downside over 1W\u20131M.", "Despite a bullish longer-term moving-average structure, the current setup looks like a pause/rollover near the pivot (~119.5) rather than a fresh upside breakout; with an impatient profile, the risk/reward is unattractive today.", "No clear event-driven catalyst in the past week, and options sentiment is unavailable, so there is limited evidence of an imminent upside trigger."]
["Trend/MAs: Bullish structure with SMA_5 > SMA_20 > SMA_200, indicating the broader trend has been up.", "Momentum: MACD histogram at -0.427 (below 0 and negatively expanding) signals deteriorating momentum and rising risk of a continued pullback.", "RSI: RSI_6 ~52 (neutral) suggests no oversold condition to support an immediate dip-buy.", "Key levels: Pivot 119.517 (price ~119.67 is essentially on it). Support at 116.182 then 114.122; resistance at 122.852 then 124.912.", "Pattern/short-term bias: Similar-pattern study suggests ~80% chance of -0.59% next day, -3.32% next week, -7.17% next month\u2014bearish near-term tilt.", "Intellectia Proprietary Trading Signals: No signal on given stock today. (- AI Stock Picker: no signal on given stock today.) (- SwingMax: No signal on given stock recently.)"]
["Strong top-line growth in the latest reported quarter (2025/Q3 revenue +35.19% YoY).", "Longer-term trend remains constructive via bullish moving averages (SMA_5 > SMA_20 > SMA_200).", "Upcoming earnings: QDEC 2025 earnings on 2026-03-03 (pre-market) with EPS estimate shown as 1.19, which could act as a catalyst if results/guide surprise positively."]
["Momentum weakening: MACD bearish and expanding to the downside, often preceding additional near-term drawdown.", "Profitability pressure in 2025/Q3: net income, EPS, and gross margin all declined YoY (margin down meaningfully).", "No news in the recent week to provide a near-term catalyst.", "Short-horizon pattern forecast leans bearish (projected declines over 1W and 1M)."]
["Latest quarter: 2025/Q3.", "Revenue: 161.343M, up 35.19% YoY (strong growth).", "Net income: 4.627M, down 13.03% YoY (profit contraction despite revenue growth).", "EPS: 1.02, down 14.29% YoY (earnings power softened).", "Gross margin: 14.72, down 23.81% YoY (key negative\u2014suggests cost/price mix pressure)."]
["Recent items show Buy ratings and higher price targets (e.g., $9 to $11) dated Dec 2025; however, the text references 'Climb Bio' and biotechnology pipelines, which does not match Climb Global Solutions (CLMB).", "Because the provided analyst notes appear to be for a different company, analyst sentiment/targets are not reliable for CLMB based on this dataset.", "Wall Street pros/cons (based on usable info here): Pros\u2014top-line growth and historically bullish trend; Cons\u2014recent profitability/margin compression and weakening near-term momentum."]
